Compositions comprising a p75 tumor necrosis factor receptor/Ig fusion protein
AssigneeImmunex Corporation
InventorsWayne Richard Gombotz, Richard L. Remmele, Jr.
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compositions comprising a p75 tumor necrosis factor receptor/Ig fusion protein.
Claims23
A pharmaceutical composition comprising a polypeptide that is an extracellular ligand-binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of a human IgG1 and from about 10 mM to about 200 mM L-arginine.
A pharmaceutical composition comprising about 10 mg/ml to about 100 mg/ml of a polypeptide that is an extracellular ligand-binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of a human IgG1, about 10 mM to about 200 mM L-arginine, and sodium phosphate, sodium chloride and sucrose.
Dependencies are inferred from the claim text.